Otsuka Corp is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Otsuka Corp in the market are multinational pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Eisai Co., Ltd. These rivals operate in similar sectors and offer a wide range of healthcare products and services. Otsuka Corp competes with these companies in terms of research and development, product innovation, market presence, and global reach. Despite the fierce competition, Otsuka Corp has established itself as a renowned player in the industry, focusing on areas like pharmaceuticals, nutraceuticals, and medical devices.

Otsuka Corp, a renowned Japanese company, has a rich history and background. Established in 1964, Otsuka Corp has been dedicated to enhancing the health and well-being of people through its diverse range of products and services. The company focuses on pharmaceuticals, nutraceuticals, and consumer products, all aimed at meeting the evolving needs of individuals worldwide. Otsuka Corp's commitment to innovation and breakthrough technologies has led to the development of groundbreaking treatments in areas such as mental health, oncology, and nephrology. With its extensive global presence, Otsuka Corp strives to make a positive impact on society by improving healthcare and contributing to the betterment of people's lives.

Otsuka Corp has achieved several significant milestones throughout its history. One noteworthy achievement is the introduction of its flagship product, Pocari Sweat, a popular electrolyte drink that has gained widespread recognition and success in the market. Additionally, the company has successfully expanded its global presence with various subsidiaries and strategic collaborations, enabling it to penetrate international markets more effectively. Otsuka Corp has also made significant advancements in the pharmaceutical industry, particularly in mental health research and development. Notably, the company introduced Abilify, a widely used medication for treating schizophrenia and bipolar disorder. The continuous dedication to innovation and strategic growth has established Otsuka Corp as a leading player in the global market.

Otsuka Corp is primarily present in Japan, where it is headquartered. The company has a strong presence in many other countries and regions as well, including the United States, China, Europe, and Southeast Asia. With its global reach and diverse operations, Otsuka Corp continues to expand its footprint and deliver its innovative products and services to customers around the world.

Otsuka Corp represents a strong set of values and a unique corporate philosophy. The company is committed to creating innovative products and services that contribute to the well-being of people worldwide. With a focus on the three values of integrity, perseverance, and entrepreneurship, Otsuka Corp strives to make a positive impact within society. By combining their expertise in various fields, the company aims to tackle global healthcare challenges and fulfill their corporate mission of improving the health and happiness of people globally. Otsuka Corp's dedication to continuous innovation and social responsibility showcases their commitment to creating a better future for all.

Analysts currently set an average price target of 3 816,37 JPY for the Otsuka stock (median: 3 876,00 JPY), implying +9,3 % versus the latest price. The consensus is based on 18 analyst ratings.

Otsuka Analyytikkojen kursstavoitteet 2026

18 analysts currently rate the Otsuka stock: 12 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Otsuka to generate revenue of 1,35 T JPY and earnings per share of 170,96 JPY.

Otsuka Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Otsuka share trades at 18,54 EUR (3 425,00 JPY).

The Otsuka share (4768.T) is listed on 3 stock exchanges, including: Frankfurt (OTK.F).

Otsuka Corp is a Japanese company that operates in various business fields. The company specializes in pharmaceuticals, nutrition, cosmetics, and beverages and operates worldwide. It is considered a global player in the industry with approximately 47,000 employees. In the pharmaceutical sector, Otsuka develops and produces innovative medications for various diseases such as neurology, oncology, cardiology, and psychiatry. Some examples include Abilify, an antipsychotic medication for schizophrenia and bipolar disorders, and Rexulti, a medication for the treatment of depression and schizophrenia. Another well-known product is the gastrointestinal medication Pletal, used for impaired blood flow. In the nutrition sector, Otsuka offers dietary supplements suitable for athletes and general use. This includes products like Pocari Sweat, a beverage containing electrolytes to prevent fluid loss during physical activity. Another product is Calorie Mate, a meal replacement supplement. Additionally, Otsuka is active in the cosmetics industry and offers numerous skincare products. Some of the notable products include the Oronine H Ointment line, which aims to help with skin conditions, injuries, and burns, and the Skin Aqua line, which serves as sun protection products. In the beverage sector, Otsuka offers natural juices and teas distributed in Japan and other countries. Otsuka Corp emphasizes intensive research and development in the development of its products. To achieve this goal, the company collaborates with renowned universities and research institutions worldwide. To ensure the quality of its products, Otsuka adheres to strict quality standards that ensure responsible practices with regard to human beings and the environment. As a globally oriented company, Otsuka is continually striving to adapt its products and services to meet the needs of its customers. To achieve this, the company works closely with local partners and experts. Overall, Otsuka's business model is characterized by intensive research and development, high-quality standards, and a wide range of products in different business sectors. The company specializes in developing innovative products that provide high value to customers. Responsible corporate governance is a key focus.

odotettu liikevaihto Otsuka on 1,35 T JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Otsuka on 65,01 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Otsuka:n hinta-voitto-suhde (P/E) on tällä hetkellä 20,03. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Otsuka-osakkeen arvostusta.

Otsuka:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,96. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Otsuka-osakkeen arvostuskennuslukuna.

Otsuka:n Eulpool-laatuscore on 8/10.

Otsuka:n ISIN on JP3188200004. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Otsuka:n WKN on 502503. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Otsuka:n ticker on 4768.T. Tämä pörssinoteeraus käytetään Otsuka-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Otsuka maksoi osinkoa 90,00 JPY . Tämä vastaa osingontuottoa noin 2,63 %. Tulevien 12 kuukauden aikana Otsuka odotetaan maksavan osinkoa 108,00 JPY.

Otsuka:n nykyinen osinkotuotto on 2,63 %.

Otsuka maksaa osinkoa, joka jaetaan kuukausina , , , .

Otsuka maksoi osinkoa joka vuosi viimeisten 26 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 108,00 JPY. Tämä vastaa osingontuottoa 3,15 %.

Otsuka kuuluu sektoriin 'Informaatioteknologia'.

Saadaksesi viimeisen osingon Otsuka:sta päivältä määrässä 45 JPY, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Vuonna 2025 Otsuka jakoi 67,5 JPY osinkona.

Otsuka:n osingot jaetaan valuutassa JPY.